---
search:
  boost: 3
---

# Diabetes – Non-Insulin

This is a subcategory of Endocrine Agents.

## Decision Pathways

- [Semaglutide (Ozempic, Rybelsus, Wegovy)](<../../Pharmacist Reference Guide/Decision Pathways/Semaglutide.md>)

## Decision Trees

### All SEMAGLUTIDES (OZEMPIC, RYBELSUS, WEGOVY) MUST BE DECISIONED USING THE SEMAGLUTIDES DECISION PATHWAY NOT TREE 

- [Endocrine - Diabetes - Non-Insulin- Non-Preferred Agents- Adlyxin, Alogliptin, Bydureon Bcise, Glucophage, Metformin ER (Generic of Fortamet, Glumetza), Metformin Sol, Mounjaro, Onglyza, Ozempic, Rybelsus, Steglatro, Symlinpen](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMVIwMlBWT1M5STNTNkdPTFBUVE5OQUdESyQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Endocrine - Diabetes - Non-Insulin- Non-Preferred Agents – Combination Agents- Alogliptin/Metformin, Glimepiride/Pioglitazone, Glyxambi, Invokamet XR, Jentadueto XR, Kombiglyze XR, Pioglitazone/Alogliptin, Qtern, Segluromet, Soliqua, Steglujan, Synjardy XR, Trijardy XR, Xigduo XR, Xultophy](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNUIzRENINzhMNkpFQlQ1Rzc3NENUQVI5OCQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                             | Generic Name                                                     |         Quantity          |        Time (Days)        |
| :---------------------------------------------------- | :--------------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Acarbose <sup>QL</sup>                                | Acarbose Tab (all strengths)                                     |            306            |            102            |
| Actoplus Met XR                                       |                                                                  |                           |                           |
| Byetta                                                |                                                                  |                           |                           |
| Farxiga                                               |                                                                  |                           |                           |
| Glimepiride <sup>QL</sup>                             | Glimepiride Tab (all strengths excl 4 MG)                        |            102            |            102            |
| Glimepiride <sup>QL</sup>                             | Glimepiride Tab 4 MG                                             |            204            |            102            |
| Glipizide <sup>QL</sup>                               | Glipizide Tab (all strengths excl 10 MG)                         |            612            |            102            |
| Glipizide <sup>QL</sup>                               | Glipizide Tab 10 MG                                              |            408            |            102            |
| Glipizide XL<sup>QL</sup>                             | Glipizide ER Tab (all strengths excl 10 MG)                      |            102            |            102            |
| Glipizide XL<sup>QL</sup>                             | Glipizide ER Tab 10 MG                                           |            204            |            102            |
| Glipizide / Metformin <sup>QL</sup>                   | Glipizide-Metformin HCI Tab (all strengths)                      |            408            |            102            |
| Glyburide <sup>QL</sup>                               | Glyburide Tab (all strengths excl 5 MG)                          |            204            |            102            |
| Glyburide <sup>QL</sup>                               | Glyburide Tab 5 MG                                               |            408            |            102            |
| Glyburide / Metformin <sup>QL</sup>                   | Glyburide-Metformin Tab (all strengths)                          | Determined pursuant to PA | Determined pursuant to PA |
| Invokamet                                             |                                                                  |                           |                           |
| Invokana                                              |                                                                  |                           |                           |
| Janumet                                               |                                                                  |                           |                           |
| Janumet XR                                            |                                                                  |                           |                           |
| Januvia                                               |                                                                  |                           |                           |
| Jardiance                                             |                                                                  |                           |                           |
| Jentadueto                                            |                                                                  |                           |                           |
| Metformin IR <sup>QL</sup>                            | Metformin HCI Tab (all strengths excl 500 MG & 850 MG)           |            204            |            102            |
| Metformin IR <sup>QL</sup>                            | Metformin HCI Tab 500 MG                                         |            408            |            102            |
| Metformin IR <sup>QL</sup>                            | Metformin HCI Tab 850 MG                                         |            306            |            102            |
| Metformin ER <sup>QL</sup> (Generic of Glucophage XR) | Metformin HCI SR Tab (all strengths excl 500 MG)                 |            204            |            102            |
| Metformin ER <sup>QL</sup> (Generic of Glucophage XR) | Metformin HCI SR Tab 500 MG                                      |            408            |            102            |
| Miglitol                                              |                                                                  |                           |                           |
| Nateglinide <sup>QL</sup>                             | Nateglinide Tab (all strengths)                                  |            306            |            102            |
| Pioglitazone <sup>QL</sup>                            | Pioglitazone HCI Tab (all strengths)                             |            102            |            102            |
| Pioglitazone / Metformin <sup>QL</sup>                | Pioglitazone HCI-Metformin HCI Tab (all strengths)               |            306            |            102            |
| Repaglinide                                           |                                                                  |                           |                           |
| Repaglinide / Metformin                               |                                                                  |                           |                           |
| Synjardy                                              |                                                                  |                           |                           |
| Tradjenta                                             |                                                                  |                           |                           |
| Trulicity <sup>QL</sup>                               | Dulaglutide Inj (all strengths)                                  |             6             |            84             |
| Victoza <sup>QL</sup>                                 | Liraglutide Soln Subcutaneous Inj (all strengths & formulations) |           30.6            |            102            |

### Non-Preferred

| Non-Preferred                                    | Generic Name                                     | Quantity | Time (Days) |
| :----------------------------------------------- | :----------------------------------------------- | :------: | :---------: |
| Adlyxin                                          |                                                  |          |             |
| Alogliptin                                       |                                                  |          |             |
| Alogliptin / Metformin                           |                                                  |          |             |
| Bydureon Bcise                                   |                                                  |          |             |
| Glimepiride / Pioglitazone                       |                                                  |          |             |
| Glucophage                                       |                                                  |          |             |
| Glyxambi                                         |                                                  |          |             |
| Invokamet XR                                     |                                                  |          |             |
| Jentadueto XR                                    |                                                  |          |             |
| Kombiglyze XR <sup>BVG (==Process by NDC== - Weekly Updates)</sup>                                   |                                                  |          |             |
| Metformin ER <sup>QL</sup> (Generic of Fortamet) | Metformin HCI SR Tab (all strengths excl 500 MG) |   204    |     102     |
| Metformin ER <sup>QL</sup> (Generic of Fortamet) | Metformin HCI SR Tab 500 MG                      |   408    |     102     |
| Metformin Sol                                    |                                                  |          |             |
| Mounjaro ==(Process by HICL)==                                         |                                                  |          |             |
| Onglyza <sup>BVG (==Process by NDC== - Weekly Updates)</sup>                                         |                                                  |          |             |
| Ozempic                                          |                                                  |          |             |
| Pioglitazone / Alogliptin                        |                                                  |          |             |
| Qtern                                            |                                                  |          |             |
| Rybelsus                                         |                                                  |          |             |
| Segluromet                                       |                                                  |          |             |
| Soliqua                                          |                                                  |          |             |
| Steglatro                                        |                                                  |          |             |
| Steglujan                                        |                                                  |          |             |
| Symlinpen                                        |                                                  |          |             |
| Synjardy XR                                      |                                                  |          |             |
| Trijardy XR                                      |                                                  |          |             |
| Xigduo XR                                        |                                                  |          |             |
| Xultophy                                         |                                                  |          |             |

## Authorizations 

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preffered Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^120 days^^ with at least ^^three preferred^^ drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)
 
[**Decision Pathaway Semaglutide (Ozempic, Rybelsus, Wegovy) 9/15/23](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Decision%20Pathways/Semaglutide/)
 
[**GLP-1 Directive for Mounjaro, Ozempic, Wegovy, Saxenda, Rybelsus, Bydureon Bcise, Adlyxin](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Medication%20Guidance/Semaglutide-Tirzepatide/) 

### Oral and Injectable Combination Drugs

Additional Oral and Injectable Combination Drugs Criteria

- Must have had a trial of at least ^^120 days^^ with the individual drugs **OR** must provide documentation of medical necessity beyond convenience for patient’s inability to use the individual drugs

### Additional Information

- An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.
- Requests may be authorized for patients with a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)
- For non-preferred drugs that have preferred drugs in the same drug class: must provide documentation that there was at least ^^one^^ inadequate clinical response with a drug in same drug class

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=49&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} </br>
[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001+UPDL+Criteria+_v2.FINAL.pdf#page=56){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=21){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
